Atossa Genetics

ATOS NASDAQ
2.170
+0.060
+2.84%
Opening 13:09 06/19 EDT
Open
2.100
Prev Close
2.110
High
2.230
Low
2.100
Volume
74.63K
Avg Vol (3M)
822.70K
52 Week High
7.39
52 Week Low
0.8000
% Turnover
0.82%
Market Cap
19.80M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Atossa Genetics ATOS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.
MORE >

Recently

Name
Price
%Change